Artelo Biosciences: Buy Rating Reiterated, PT Raised to $18 by D. Boral Capital.

Artelo Biosciences: Buy Rating Reiterated, PT Raised to $18 by D. Boral Capital.

Artelo Biosciences, Inc. (Nasdaq: ARTL) has seen its buy rating reiterated by D. Boral Capital, with the price target raised to $18. The move comes following the company's recent announcement of positive results from an initial food effect investigation with ART26.12, a novel non-opioid treatment candidate for persistent pain [2].

The study, conducted as part of the successful single ascending dose (SAD) Phase 1 clinical trial, assessed the pharmacokinetics and safety profile of ART26.12 in healthy volunteers under both fed and fasted conditions. Key findings include a favorable safety profile, consistent exposure levels under fasted conditions, and predictable pharmacokinetic behavior, which supports the potential for ART26.12 to be administered with or without food [2].

Preparations are underway to initiate a multiple ascending dose (MAD) study to further evaluate the safety, tolerability, and pharmacokinetics of ART26.12 with repeated dosing over time. The MAD study is planned to commence dosing subjects in the fourth quarter of this year [2].

ART26.12 is a selective, orally administered, and peripherally acting FABP5 inhibitor, representing a new therapeutic class with a non-opioid, non-steroidal analgesic approach designed to target a novel mechanism in pain modulation by altering endogenous lipid species in pain-relevant tissues [2]. The initial clinical development planned is for chemotherapy-induced peripheral neuropathy (CIPN), with additional therapeutic promise shown for the treatment of certain cancers, neuropathic and nociceptive pain, psoriasis, and anxiety disorders [2].

Artelo Biosciences is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. The company has adopted a forward-looking corporate finance initiative, deploying a portion of its excess capital into Solana under a digital asset treasury strategy to enhance liquidity management and position the company for long-term value creation [1].

The buy rating and raised price target reflect investor optimism in Artelo Biosciences' pipeline and the potential of ART26.12 to address significant unmet needs in pain management and other therapeutic areas.

References:
[1] https://www.nasdaq.com/market-activity/stocks/artl/analyst-research
[2] https://www.globenewswire.com/news-release/2025/08/25/3138375/0/en/Artelo-Biosciences-Announces-New-Data-from-an-Initial-Food-Effect-Investigation-with-ART26-12-a-Novel-Non-Opioid-Treatment-Candidate-for-Persistent-Pain.html